What is OSE Immunotherapeutics?
Founded in 2012, OSE Immunotherapeutics operates as an integrated biotechnology entity dedicated to the modulation of the immune system. The company specializes in the discovery and development of novel therapies targeting immuno-oncology and severe autoimmune conditions. By leveraging a robust R&D platform, OSE Immunotherapeutics maintains a competitive edge in the life sciences sector, focusing on high-unmet-need therapeutic areas. Its business model emphasizes both internal innovation and strategic partnerships with global pharmaceutical players to bring complex treatments to market efficiently.
The company's commitment to scientific rigor has established it as a pivotal player in the French biotech ecosystem. By focusing on immune-checkpoint inhibitors and other advanced modalities, OSE Immunotherapeutics continues to refine its portfolio, ensuring that its therapeutic candidates address the evolving requirements of modern medicine while maintaining a sustainable growth trajectory.
How much funding has OSE Immunotherapeutics raised?
OSE Immunotherapeutics has raised a total of $9M across 1 funding round:
Other Financing Round
$9M
Other Financing Round (2024): $9M with participation from Bpifrance
Key Investors in OSE Immunotherapeutics
Bpifrance
A French public investment bank that provides credit, guarantees, and equity to support the growth and international expansion of innovative companies.
What's next for OSE Immunotherapeutics?
With the recent influx of capital, OSE Immunotherapeutics is poised to transition into a more aggressive phase of clinical execution. The strategic roadmap likely involves the advancement of lead assets through critical trial phases and the potential expansion of its collaborative network. As the company navigates the complexities of late-stage development, the focus will remain on achieving regulatory milestones and optimizing its therapeutic pipeline for commercial viability. This financial support provides the necessary runway to sustain long-term research initiatives and solidify the company's standing as a premier innovator in the immunology space.
See full OSE Immunotherapeutics company page
